Cascade-Responsive Nanoparticles for Efficient CRISPR/Cas9-Based Glioblastoma Gene Therapy.

Area of Science:

• Biomedical Engineering
• Nanotechnology
• Cancer Therapy

Background:

• Glioblastoma (GBM) is a fatal brain cancer with limited treatment options.
• CRISPR/Cas9 gene editing offers potential for permanent GBM treatment by targeting pathogenic genes.
• Effective and safe delivery of CRISPR/Cas9 across the blood-brain barrier (BBB) to GBM remains a significant challenge.

Purpose of the Study:

• To design a glycosylated and cascade-responsive nanoparticle (GCNP) for targeted CRISPR/Cas9 delivery to GBM.
• To ensure the nanoparticle can cross the BBB and activate gene editing specifically within the GBM microenvironment.
• To evaluate the therapeutic efficacy of GCNP-mediated CRISPR/Cas9 targeting PD-L1 in GBM models.

Main Methods:

• Development of a GCNP with a cationic polyplex core and a glycosylated polymer layer.
• Designing the GCNP for cascading response to low pH and high glutathione (GSH) concentration for controlled release.
• In vivo studies in GBM-bearing mice to assess BBB penetration, GBM targeting, tumor inhibition, and survival rates, often in combination with temozolomide (TMZ).

Main Results:

• The GCNP successfully crossed the BBB and demonstrated targeted activation of CRISPR/Cas9 within the GBM.
• The GCNP system effectively inhibited GBM tumor growth.
• Combination therapy with GCNP and temozolomide significantly prolonged the survival time of GBM-bearing mice.

Conclusions:

• GCNPs represent a promising strategy for overcoming BBB delivery challenges in GBM gene therapy.
• The cascade-responsive nature of GCNPs allows for precise spatiotemporal control of CRISPR/Cas9 activation in the tumor microenvironment.
• Targeting PD-L1 with GCNP-mediated CRISPR/Cas9, in conjunction with TMZ, shows significant therapeutic potential for glioblastoma.